Testosterone or “T” treatments have been linked to cardiac problems. LA January 29, 2014 study on the impact of testosterone treatments confirmed prior research suggesting testosterone therapy may elevate the risk of heart problems. Younger men with a history of heart disease are at increased risk, as are both middle-aged and older men.
In response to mounting concerns about Testosterone therapy products, the FDA announced on January 31, 2014 that an investigation into T-therapy side effects would be launched. The FDA planned to investigate the risk of stroke, cardiac arrest, and death in testosterone-therapy users.
Gels, pellets, injections, and patches are all prescription testosterone therapies that may have unexpected and dangerous side effects. Prescription “T” treatments that may be linked to an increased danger of heart problems include but are not limited to Androderm (Actavis Inc.); Axiron (Eli Lilly); Fortesta (Endo Pharm); Striant (Actient Pharm); and Testim (Auxilium Pharm). The FDA announced in June of 2014 that these and other testosterone drugs will be required to carry expand warnings on the increased possibility of blood clots forming in the veins.
Lawyers are pursuing cases in which male users of testosterone therapies have suffered heart attacks, strokes, and blood clots including PEs and DVTs.
